Recursion Pharmaceuticals, Inc. RXRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $66.41M-11.1% | $74.68M+70.9% | $43.69M-32.4% | $64.6M+8.0% | $59.79M+1.6% | ||
| $61.61M-13.2% | $70.95M+2.1% | $69.47M+3.9% | $66.86M+19.6% | $55.9M+23.6% | ||
| $4.8M+28.6% | $3.73M— | —— | —— | —— | ||
| 7.2%+2.2pp | 5%— | —— | —— | —— | ||
| $433.53M-8.8% | $475.27M-0.5% | $477.67M+10.8% | $431.2M+14.5% | $376.5M+19.7% | ||
| $156.53M-11.4% | $176.59M-19.8% | $220.12M+1.8% | $216.25M+7.4% | $201.43M+13.0% | ||
| $651.68M-9.8% | $722.81M-5.8% | $767.25M+7.4% | $714.31M+12.7% | $633.82M+17.8% | ||
| -$585.27M+9.7% | -$648.13M+10.4% | -$723.57M-11.4% | -$649.72M-13.2% | -$574.03M-19.8% | ||
| -881.3%-13.5pp | -867.9%+788pp | -1,656.2%-650pp | -1,005.8%-45.7pp | -960.1%-146pp | ||
| $20.91M+546% | $3.24M-58.9% | $7.87M+1,210% | $601K+148% | -$1.25M-109% | ||
| -$564.36M+12.5% | -$644.89M+9.9% | -$715.69M-10.3% | -$649.12M-12.8% | -$575.28M-23.8% | ||
| —— | —— | -$155K-1,822% | $9K+102% | -$514K+54.7% | ||
| -$559.78M+13.2% | -$644.76M+9.9% | -$715.54M-10.2% | -$649.13M-12.9% | -$574.78M-24.0% | ||
| -842.9%+20.4pp | -863.4%+774pp | -1,637.8%-633pp | -1,004.9%-43.6pp | -961.3%-173pp | ||
| -$1.16+19.4% | -$1.44+21.7% | -$1.84-1.1% | -$1.82-0.6% | -$1.81-6.5% | ||
| -$1.16+19.4% | -$1.44+21.7% | -$1.84-1.1% | -$1.82-0.6% | -$1.81-6.5% | ||
| 1.8B+7.4% | 1.7B+11.2% | 1.5B+11.9% | 1.4B+14.6% | 1.2B+16.1% | ||
| 1.8B+7.4% | 1.7B+11.2% | 1.5B+11.9% | 1.4B+14.6% | 1.2B+16.1% | ||
| $66.41M-11.1% | $74.68M+70.9% | $43.69M-32.4% | $64.6M+8.0% | $59.79M+1.6% | ||
| -$585.27M+9.7% | -$648.13M+10.4% | -$723.57M-11.4% | -$649.72M-13.2% | -$574.03M-19.8% | ||
| -$501.23M+11.2% | -$564.43M+12.7% | -$646.39M-10.2% | -$586.39M-11.6% | -$525.59M-18.8% | ||
| -$501.23M+11.2% | -$564.43M+12.7% | -$646.39M-10.2% | -$586.39M-11.6% | -$525.59M-18.8% | ||
| -754.8%+1.0pp | -755.8%+724pp | -1,479.5%-572pp | -907.8%-28.7pp | -879.1%-127pp | ||
| -$585.27M+9.7% | -$648.13M+10.4% | -$723.57M-11.4% | -$649.72M-13.2% | -$574.03M-19.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s revenue?
- Recursion Pharmaceuticals, Inc. (RXRX) generated $66.4M in revenue over the trailing twelve months, up 11.1% year over year.
- Is Recursion Pharmaceuticals, Inc. profitable?
- Recursion Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $559.8M over the trailing twelve months, a -842.9% net margin.
- What are Recursion Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 7.2% and operating margin is -881.3%, with a -842.9% net margin.
- What is Recursion Pharmaceuticals, Inc.'s earnings per share?
- Recursion Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.16.
- Where does Recursion Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
